Why Is Pasithea Therapeutics Stock Surging On Thursday?
Portfolio Pulse from Vandana Singh
Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced positive data from its Phase 1 trial of PAS-004, leading to a significant surge in its stock price. The trial showed promising safety, tolerability, and pharmacokinetic results, with no adverse events reported. The stock rose by 71.70% on high trading volume.
September 26, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics' stock surged by 71.70% following the release of positive Phase 1 trial data for PAS-004, which showed promising safety and efficacy results. The trial indicated no treatment-related adverse events and a favorable safety profile, boosting investor confidence.
The announcement of positive trial results for PAS-004, with no adverse events and promising efficacy, has led to a significant increase in KTTA's stock price. The high trading volume and the CEO's optimistic comments further support the positive market reaction.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100